Increasing Prevalence of Infectious Diseases to Augment the Point-of-Care (POC) Infectious Disease Diagnostics Market Growth

Point-of-Care (POC) Infectious Disease Diagnostics


 Point-of-care (POC) diagnosis includes sample testing to facilitate rapid diagnosis and decide on treatment planning accordingly. Infectious diseases often need to be diagnosed early, as they can be fatal against the immune system. POC infectious disease diagnostics allows early detection of diseases and can impact the medical outcome of treatment of the disease.

The U.S. FDA (United States Food and Drug Administration) is responsible for overseeing all activities related to the marketing of diagnostic products. POC diagnosis is cost-efficient and time saving, as well as offer various benefits such as can be performed easily, prevent sample spillage, no necessity of skilled professionals, etc.

Market Dynamics:

The emergence of COVID-19 (SARS-CoV-2) is expected to propel the growth of the point-of-care (POC) infectious disease diagnostics market. For instance, in February 2021, RNA Disease Diagnostics secured an exclusive global license to a cutting-edge sensor technology jointly owned by the University of Maryland, Baltimore County (UMBC) and the University of Maryland, Baltimore (UMB). RNA Disease Diagnostics’ first product will be a rapid point-of-care (POC) COVID-19 test with accuracy, sensitivity, and specificity that is comparable to the gold standard RT-PCR lab diagnostic.

Moreover, initiatives and funding from government and individual organizations for point-of-care (POC) infectious disease diagnostics are expected to augment the growth of the point-of-care (POC) infectious disease diagnostics market. For instance, in February 2021, Visby Medical secured US$ 12.3 million from the United States Biomedical Advanced Research and Development Authority to develop a next generation device to detect influenza and COVID-19 in a single point-of-care rapid PCR test and, subsequently, as an over-the-counter test for consumer use.

Increasing prevalence of infectious diseases in both developed and developing countries and increasing incidence of target conditions is also expected to fuel the growth of the point-of-care (POC) infectious disease diagnostics market. However, stringent and time-consuming regulatory policies and pricing pressure due to reimbursement cuts and budget constraints are expected to restrain the market growth.

Competitive Analysis:

Major players operating in the point-of-care (POC) infectious disease diagnostics market are Cardinal Health, Inc., AccuBioTech Co., Ltd., Trinity Biotech Plc., Thermo Fisher Scientific, Becton, Dickinson, and Company, Hoffman-La Roche Ltd., Alcon Laboratories, Inc., Abbott Laboratories, and Danaher Corporation.

Major players in the market are adopting various strategies, such as merger, acquisition, and collaboration, to enhance their market presence. For instance, in January 2021, Thermo Fisher Scientific announced a definitive agreement to acquire molecular diagnostics company Mesa Biotech for approximately US$ 450 million.

In September 2019, Abbott Laboratories and Sanofi collaborated to integrate glucose sensing and insulin delivery technologies to further simplify diabetes management.

Comments

Popular posts from this blog

Bourbon Whiskey Is the Most Popular Whiskey in America and In Many Other Countries around the World

Viral Vectors And Plasmid DNA Manufacturing Market Is Gaining Major Traction With Oxford Biomedica Plc Entering Into A 3-Year Agreement With Boehringer Ingelheim For The Manufacture And Supply Of Various Types Of Viral Vectors

Hard Surface Flooring Market Is Expected To Witness Robust Growth As Mohawk Industries Introduces Newly Imagined 30,000-Square Foot Floor Space At The International Surface Event (TISE)